121 related articles for article (PubMed ID: 33790151)
1. [The Efficacy of topo Ⅰ-pS10 Expression in Gastric Cancer as a Predictive Biomarker for Irinotecan Use].
Ando K; Hu Q; Fujimoto Y; Jogo T; Nakanishi R; Hisamatsu Y; Kimura Y; Oki E; Bharti A; Mori M
Gan To Kagaku Ryoho; 2021 Mar; 48(3):331-335. PubMed ID: 33790151
[TBL] [Abstract][Full Text] [Related]
2. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Ozonoff A; Lee SY; Voisine M; Parker JT; Nakanishi R; Nishimura S; Yang J; Grace Z; Tran B; Diefenbach TJ; Maehara Y; Yasui H; Irino T; Salgia R; Terashima M; Gibbs P; Ramanathan RK; Oki E; Mori M; Kulke M; Hartshorn K; Bharti A
Clin Colorectal Cancer; 2021 Jun; 20(2):e129-e138. PubMed ID: 33731288
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.
Bandyopadhyay K; Gjerset RA
Biochemistry; 2011 Feb; 50(5):704-14. PubMed ID: 21182307
[TBL] [Abstract][Full Text] [Related]
4. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Xu JM; Zhu BD; Mangia A; Simone G; Montemurro S; Giuliani F; Maiello E; Colucci G; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):312-5. PubMed ID: 15996331
[TBL] [Abstract][Full Text] [Related]
7. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Shen J; Wei J; Wang H; Yue G; Yu L; Yang Y; Xie L; Zou Z; Qian X; Ding Y; Guan W; Liu B
J Transl Med; 2013 Mar; 11():73. PubMed ID: 23517622
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
9. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Bai M; Goussia A; Samantas E; Galani E; Tsavdaridis D; Karina M; Papakostas P; Konstantara A; Fountzilas G
Anticancer Res; 2007; 27(4C):2973-83. PubMed ID: 17695481
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
11. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Shaojun C; Li H; Haixin H; Guisheng L
Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
[TBL] [Abstract][Full Text] [Related]
12. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
13. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Ohashi N; Fujiwara Y; Yamaoka N; Katoh O; Satow Y; Yamakido M
Jpn J Cancer Res; 1996 Dec; 87(12):1280-7. PubMed ID: 9045964
[TBL] [Abstract][Full Text] [Related]
14. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
15. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
16. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
17. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
Khadka DB; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
[TBL] [Abstract][Full Text] [Related]
18. CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
Nakajima Y; Miyake S; Nagai K; Kawano T; Iwai T
Jpn J Cancer Res; 2001 Dec; 92(12):1335-41. PubMed ID: 11749700
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Horisberger K; Erben P; Muessle B; Woernle C; Stroebel P; Kaehler G; Wenz F; Hochhaus A; Post S; Willeke F; Hofheinz RD;
Anticancer Drugs; 2009 Jul; 20(6):519-24. PubMed ID: 19436196
[TBL] [Abstract][Full Text] [Related]
20. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Kubota N; Kanzawa F; Nishio K; Takeda Y; Ohmori T; Fujiwara Y; Terashima Y; Saijo N
Biochem Biophys Res Commun; 1992 Oct; 188(2):571-7. PubMed ID: 1332703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
